Mr. Glenn Saldanha Honoured With 'Swiss Ambassador's Award for
Exceptional Innovation'
MUMBAI, November 30, 2012 /PRNewswire/ --
Mr. Glenn Saldanha Becomes the Third
Recipient of This Prestigious Award After Mr. Ratan Tata, Chairman,
Tata Group in 2011 and Mr.
Yash Chopra in 2010
Swiss Ambassador Dr. Linus von Castelmur honoured Mr.
Glenn Saldanha, Chairman &
Managing Director, Glenmark Pharmaceuticals Limited with 'Swiss
Ambassador's Award for Exceptional Innovation' for his outstanding
innovation-driven leadership on November 29,
2012 at an event organised at the Embassy of Switzerland in New
Delhi.
Acknowledging Mr. Glenn
Saldanha's contributions in the area of innovation
Ambassador Dr. Linus von Castelmur said, "Innovation has become the
new driving force of Indo-Swiss Partnership and Glenmark is a very
good case in point. Glenmark Pharmaceuticals was the first Indian
life science enterprise to establish a research and development
facility outside India in 2006.
Glenmark's 3,000 sq. m. state of the art laboratory in La
Chaux-de-Fonds employs 60 highly qualified scientists."
In his acceptance speech Mr. Glenn
Saldanha said, "I am deeply honored to receive the Swiss
Ambassador's Award for exceptional innovation. This award is even
more meaningful because it's being presented by a country which is
one of the leading innovation research destinations for the
pharmaceutical industry, offering the best combination of
infrastructure and talent for new drug discovery research. This has
been demonstrated by the success achieved by Glenmark in
Switzerland."
Mr. Saldanha added, "Glenmark's novel Biologics Research Centre
at Neuchatel, Switzerland has been
doing some cutting-edge research work in the area of novel
biologics which resulted in our company signing a landmark
agreement with Sanofi of France.
This was the first outlicencing deal executed by an Indian company
and the largest deal across emerging markets in the area of novel
biologics. Innovation leading to new drugs is critical to meeting
the global unmet medical need and recognitions like these inspire
us to continue our work in the area of innovation or drug discovery
research."
Earlier in his laudatory speech Mr. Ranjit Shahani, President of Organisation of
Pharmaceutical Producers of India
expressed that it has been Mr. Saldanha's endeavour to serve people
with low-cost medication. He has personally focused his energies on
research in therapeutic areas such as pain, inflammation and
oncology. He remarked that Glenmark is one of the few Indian
companies to have developed and licensed out six molecules to what
is popularly known as Big Pharma.
Swiss Ambassador's Award recognises individuals who have
contributed to the promotion of Indo-Swiss bilateral relations or
have stood out for their exceptional role in the society and
industry. Swiss Ambassador's Award 2011 for exceptional leadership
was conferred on Mr. Ratan Tata, Chairman, Tata Group and the award for the year 2010 was
presented to Mr. Yash Chopra for his
remarkable contribution to Indo-Swiss people to people relations
through his movies.
About Glenmark:
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven,
global, integrated pharmaceutical company headquartered at
Mumbai, India. It is ranked among
the top 100 pharma & biotech companies of the world in terms of
revenues. (SCRIP 100 Rankings published in the year 2012) Glenmark
is a leading player in the discovery of new molecules both NCEs
(new chemical entity) and NBEs (new biological entity). Glenmark
has several molecules in various stages of clinical development and
is primarily focused in the areas of inflammation [asthma/COPD,
rheumatoid arthritis etc.] and Pain [neuropathic pain and
inflammatory pain]. The company has a significant presence in
branded generics markets across emerging economies including
India. GPL along with its
subsidiary has 13 manufacturing facilities in four countries and
has five R&D centers. Its subsidiary, Glenmark Generics Limited
services the requirements of the US and Western Europe generics markets. The API
business sells its products in over 80 countries, including the US,
various countries in the EU, South
America and India.
Primary Media Contact: Corporate Communications,
corpcomm@glenmarkpharma.com, 91-22-40189999